Unknown

Dataset Information

No calcitonin change in a person taking dulaglutide diagnosed with pre-existing medullary thyroid cancer.


ABSTRACT:

Background

Glucagon-like peptide-1 receptor agonists, such as dulaglutide, exenatide and liraglutide, are approved to treat Type 2 diabetes mellitus. Although these drugs provide substantial glycaemic control, studies in rodents have prompted concerns about the development of medullary thyroid carcinoma. These data are reflected in the US package insert, with boxed warnings and product labelling noting the occurrence of these tumours after clinically relevant exposures in rodents, and contraindicating glucagon-like peptide-1 receptor agonist use in people with a personal or family history of medullary thyroid carcinoma, or in people with multiple endocrine neoplasia type 2. However, there are substantial differences between rodent and human responses to glucagon-like peptide-1 rece

SUBMITTER: Sherman SI 

PROVIDER: S-EPMC5838554 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature